PPARα is known to be modulated in neurologic disease, including AD (Fanelli et al., 2013; Porcellotti et al., 2015), and several studies emphasize the possible treatment of AD based on PPARα natural or synthetic ligands (Santos et al., 2005; Inestrosa et al., 2013; Fidaleo et al., 2014; D'Orio et al., 2018). Here, PPARA is linked to nervous system disorder.